Research Analysts’ Recent Ratings Updates for Glaukos (GKOS)

A number of firms have modified their ratings and price targets on shares of Glaukos (NYSE: GKOS) recently:

  • 11/16/2026 – Glaukos had its price target raised by BTIG Research from $234.00 to $252.00. They now have a “buy” rating on the stock.
  • 11/7/2026 – Glaukos was upgraded by Wall Street Zen from “buy” to “strong-buy”.
  • 10/29/2026 – Glaukos had its price target raised by HC Wainwright from $195.00 to $248.00. They now have a “buy” rating on the stock.
  • 10/29/2026 – Glaukos had its price target raised by Citigroup from $225.00 to $247.00. They now have a “buy” rating on the stock.
  • 10/29/2026 – Glaukos had its “overweight” rating reaffirmed by Piper Sandler. They now have a $240.00 price target on the stock, up from $195.00.
  • 10/29/2026 – Glaukos was given a new $225.00 price target by Mizuho.
  • 10/29/2026 – Glaukos had its price target raised by Truist Financial from $215.00 to $255.00. They now have a “buy” rating on the stock.
  • 10/29/2026 – Glaukos had its price target raised by JPMorgan Chase & Co. from $200.00 to $240.00. They now have an “overweight” rating on the stock.
  • 10/29/2026 – Glaukos had its price target raised by Wells Fargo & Company from $178.00 to $226.00. They now have an “overweight” rating on the stock.
  • 10/29/2026 – Glaukos had its price target raised by Stifel Nicolaus from $190.00 to $225.00. They now have a “buy” rating on the stock.
  • 10/29/2026 – Glaukos had its price target raised by BTIG Research from $205.00 to $234.00. They now have a “buy” rating on the stock.
  • 10/29/2026 – Glaukos had its price target raised by Needham & Company LLC from $201.00 to $251.00. They now have a “buy” rating on the stock.
  • 10/28/2026 – Glaukos was upgraded by Zacks Research from “hold” to “strong-buy”.
  • 10/15/2026 – Glaukos had its “sell (d-)” rating reaffirmed by Weiss Ratings.
  • 10/13/2026 – Glaukos was given a new $190.00 price target by Mizuho.
  • 10/12/2026 – Glaukos had its price target raised by BTIG Research from $202.00 to $205.00. They now have a “buy” rating on the stock.
  • 9/22/2026 – Glaukos had its price target raised by Jefferies Financial Group from $190.00 to $210.00. They now have a “buy” rating on the stock.

Glaukos Stock Performance

Glaukos stock opened at $232.59 on Thursday. Glaukos Corporation has a fifty-two week low of $91.83 and a fifty-two week high of $255.18. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.09 and a current ratio of 4.57. The stock has a market cap of $13.77 billion, a P/E ratio of -79.11 and a beta of 0.68. The firm’s fifty day moving average price is $188.17 and its 200-day moving average price is $148.89.

Glaukos (NYSE:GKOS – Get Free Report) last announced its earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.57. The company had revenue of $211.03 million during the quarter, compared to analyst estimates of $168.04 million. Glaukos had a negative net margin of 24.60% and a negative return on equity of 0.97%. The firm’s quarterly revenue was up 58.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.16) earnings per share. On average, equities research analysts expect that Glaukos Corporation will post 0.50 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Gilbert H. Kliman sold 2,500 shares of Glaukos stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $253.00, for a total value of $632,500.00. Following the transaction, the director owned 37,406 shares in the company, valued at $9,463,718. This trade represents a 6.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Joseph Gilliam sold 861 shares of Glaukos stock in a transaction on Monday, November 16th. The stock was sold at an average price of $250.00, for a total transaction of $215,250.00. Following the completion of the transaction, the chief operating officer owned 71,602 shares in the company, valued at approximately $17,900,500. The trade was a 1.19% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 48,278 shares of company stock valued at $11,911,705 in the last ninety days. 5.90% of the stock is owned by corporate insiders.

Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.

Read More

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.